TIDMPRTC
PureTech Health PLC
10 February 2021
10 February 2021
PureTech Health plc
PureTech Founded Entity Vor Biopharma Closes Over $200M Initial
Public Offering
PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics company dedicated to
discovering, developing and commercializing highly differentiated
medicines for devastating diseases , is pleased to note that its
Founded Entity, Vor Biopharma (Nasdaq: VOR), announced the closing
of its previously announced initial public offering of 9,828,017
shares of its common stock, plus an additional 1,474,202 shares
sold pursuant to the full option exercised by the underwriters, at
a price to the public of $18.00 per share. The aggregate gross
proceeds to Vor from the offering, before deducting the
underwriting discounts and commissions and other offering expenses
payable by Vor, were approximately $203.4 million. The shares began
trading on the Nasdaq Global Market on Friday, February 5, 2021
under the ticker symbol "VOR".
Following the closing, PureTech holds 3,207,200 shares of Vor
common stock.
The full text of the announcement from Vor is as follows:
Vor Biopharma Closes Over $200M Initial Public Offering,
Including Full Exercise of Option to Purchase Additional Shares
CAMBRIDGE, Mass., Feb. 9, 2021 - Vor Biopharma (Nasdaq: VOR), a
cell therapy company pioneering engineered hematopoietic stem cell
(eHSC) therapies combined with targeted therapies for the treatment
of cancer, today announced the closing of its previously announced
initial public offering of 9,828,017 shares of its common stock,
plus an additional 1,474,202 shares sold pursuant to the full
option exercised by the underwriters, at a price to the public of
$18.00 per share. The aggregate gross proceeds to Vor from the
offering, before deducting the underwriting discounts and
commissions and other offering expenses payable by Vor, were
approximately $203.4 million. The shares began trading on the
Nasdaq Global Market on Friday, February 5, 2021 under the ticker
symbol "VOR".
Goldman Sachs & Co. LLC, Evercore ISI, Barclays and Stifel
acted as joint book-running managers for the offering.
Registration statements relating to the securities sold in this
offering have been filed with the Securities and Exchange
Commission (SEC) and have become effective. Copies of the
registration statements can be accessed through the SEC's website
at www.sec.gov. This offering was made only by means of a
prospectus forming part of the effective registration statements
relating to these shares. Copies of the final prospectus may be
obtained from Goldman Sachs & Co. LLC, Attention: Prospectus
Department, 200 West Street, New York, New York 10282, via
telephone at 1-866-471-2526, or via email at
prospectus-ny@ny.email.gs.com; Evercore Group L.L.C., Attention:
Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York,
New York 10055, via telephone at 1-888-474-0200, or via email at
ecm.prospectus@evercore.com; Barclays Capital Inc., Attention:
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
New York 11717, via telephone at 1-888-603-5847, or via email at
Barclaysprospectus@broadridge.com; or Stifel, Nicolaus &
Company, Incorporated, Attention: Syndicate, One Montgomery Street,
Suite 3700, San Francisco, California 94104, via telephone at
1-415-364-2720, or via email at syndprospectus@stifel.com.
This press release shall not constitute an offer to sell, or a
solicitation of an offer to buy these securities, nor shall there
be any offer or sale of, these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or jurisdiction.
About Vor Biopharma
Vor Biopharma is a cell therapy company that aims to transform
the lives of cancer patients by pioneering engineered hematopoietic
stem cell (eHSC) therapies to create next-generation,
treatment-resistant transplants that unlock the potential of
targeted therapies. By removing biologically redundant proteins
from eHSCs, we design these cells and their progeny to be
treatment-resistant to complementary targeted therapies, thereby
enabling these therapies to selectively destroy cancerous cells
while sparing healthy cells.
Ownership Information and Other Required Disclosures
After giving effect to the IPO closing, PureTech owns 3,207,200
shares of common stock representing approximately 8.6% of Vor's
outstanding shares.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercializing highly
differentiated medicines for devastating diseases, including
intractable cancers, lymphatic and gastrointestinal diseases,
central nervous system disorders and inflammatory and immunological
diseases, among others. The Company has created a broad and deep
pipeline through the expertise of its experienced research and
development team and its extensive network of scientists,
clinicians and industry leaders. This pipeline, which is being
advanced both internally and through PureTech's Founded Entities,
as of the date of PureTech's most recently filed Registration
Statement on Form 20-F, was comprised of 24 products and product
candidates, including two that have received FDA clearance and
European marketing authorization. All of the underlying programs
and platforms that resulted in this pipeline of product candidates
were initially identified or discovered and then advanced by the
PureTech team through key validation points based on the Company's
unique insights into the biology of the brain, immune and gut, or
BIG, systems and the interface between those systems, referred to
as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, our expectations regarding the potential therapeutic benefits
of our product candidates, our expectations regarding Vor's closing
of its initial public offering and those risks and uncertainties
described in the risk factors included in the regulatory filings
for PureTech Health plc. These forward-looking statements are based
on assumptions regarding the present and future business strategies
of the company and the environment in which it will operate in the
future. Each forward-looking statement speaks only as at the date
of this press release. Except as required by law and regulatory
requirements, neither the company nor any other party intends to
update or revise these forward-looking statements, whether as a
result of new information, future events or otherwise.
Contact:
Investors
Allison Mead Talbot
+1 617 651 3156
amt@puretechhealth.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFIFEIFDIILIL
(END) Dow Jones Newswires
February 10, 2021 02:05 ET (07:05 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Oct 2024 to Nov 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Nov 2023 to Nov 2024
